MicroRNA-mediated regulation of BCL-2 in breast cancer

Breast cancer, a prominent form of cancer in women, arises from the inner lining of mammary glands, ducts, and lobules. With an approximate prevalence rate of 1 in 8 women, the standard treatment methods for this condition include the surgical excision of afflicted tissues, chemotherapy, radiation,...

Full description

Saved in:
Bibliographic Details
Main Authors: Kannan Mayuri, Sundaram Vickram, Thirunavukarasou Anand, Konda Mani Saravanan
Format: Article
Language:English
Published: AIMS Press 2025-01-01
Series:AIMS Molecular Science
Subjects:
Online Access:https://www.aimspress.com/article/doi/10.3934/molsci.2025003
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125027607838720
author Kannan Mayuri
Sundaram Vickram
Thirunavukarasou Anand
Konda Mani Saravanan
author_facet Kannan Mayuri
Sundaram Vickram
Thirunavukarasou Anand
Konda Mani Saravanan
author_sort Kannan Mayuri
collection DOAJ
description Breast cancer, a prominent form of cancer in women, arises from the inner lining of mammary glands, ducts, and lobules. With an approximate prevalence rate of 1 in 8 women, the standard treatment methods for this condition include the surgical excision of afflicted tissues, chemotherapy, radiation, and hormone therapy. The BCL-2 gene, also known as the B cell lymphoma gene, prevents apoptosis in eukaryotic cells. It is commonly found to be excessively active in many types of malignancies, such as leukemia, carcinomas, and breast cancer. The excessive expression of this gene has a role in the advancement of cancer by inhibiting apoptosis. Recent research emphasizes the function of microRNAs (miRs) in regulating the expression of BCL-2. These miRs can either decrease or increase the activity of specific genes involved in programmed cell death, thus making them potential targets for therapeutic interventions. This review explicitly examines the regulatory impacts of several miRs on BCL-2, thereby investigating their ability to trigger apoptosis and function as targeted treatments for breast cancer. By comprehending the complex interplay between miRs and BCL-2, it is possible to devise novel therapeutic approaches that can augment the efficacy of breast cancer treatments, thus eventually enhancing patient outcomes.
format Article
id doaj-art-7296b2a255db49a2a1166bd33a61353c
institution OA Journals
issn 2372-0301
language English
publishDate 2025-01-01
publisher AIMS Press
record_format Article
series AIMS Molecular Science
spelling doaj-art-7296b2a255db49a2a1166bd33a61353c2025-08-20T02:34:12ZengAIMS PressAIMS Molecular Science2372-03012025-01-01121324810.3934/molsci.2025003MicroRNA-mediated regulation of BCL-2 in breast cancerKannan Mayuri0Sundaram Vickram1Thirunavukarasou Anand2Konda Mani Saravanan3Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai 602105, Tamil Nadu, IndiaDepartment of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai 602105, Tamil Nadu, IndiaSRIIC Lab, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai 600116, Tamil Nadu, IndiaDepartment of Biotechnology, Bharath Institute of Higher Education and Research, Chennai 600073, Tamil Nadu, IndiaBreast cancer, a prominent form of cancer in women, arises from the inner lining of mammary glands, ducts, and lobules. With an approximate prevalence rate of 1 in 8 women, the standard treatment methods for this condition include the surgical excision of afflicted tissues, chemotherapy, radiation, and hormone therapy. The BCL-2 gene, also known as the B cell lymphoma gene, prevents apoptosis in eukaryotic cells. It is commonly found to be excessively active in many types of malignancies, such as leukemia, carcinomas, and breast cancer. The excessive expression of this gene has a role in the advancement of cancer by inhibiting apoptosis. Recent research emphasizes the function of microRNAs (miRs) in regulating the expression of BCL-2. These miRs can either decrease or increase the activity of specific genes involved in programmed cell death, thus making them potential targets for therapeutic interventions. This review explicitly examines the regulatory impacts of several miRs on BCL-2, thereby investigating their ability to trigger apoptosis and function as targeted treatments for breast cancer. By comprehending the complex interplay between miRs and BCL-2, it is possible to devise novel therapeutic approaches that can augment the efficacy of breast cancer treatments, thus eventually enhancing patient outcomes.https://www.aimspress.com/article/doi/10.3934/molsci.2025003oncologymirbcl-2 genebreast cancertargeted therapy
spellingShingle Kannan Mayuri
Sundaram Vickram
Thirunavukarasou Anand
Konda Mani Saravanan
MicroRNA-mediated regulation of BCL-2 in breast cancer
AIMS Molecular Science
oncology
mir
bcl-2 gene
breast cancer
targeted therapy
title MicroRNA-mediated regulation of BCL-2 in breast cancer
title_full MicroRNA-mediated regulation of BCL-2 in breast cancer
title_fullStr MicroRNA-mediated regulation of BCL-2 in breast cancer
title_full_unstemmed MicroRNA-mediated regulation of BCL-2 in breast cancer
title_short MicroRNA-mediated regulation of BCL-2 in breast cancer
title_sort microrna mediated regulation of bcl 2 in breast cancer
topic oncology
mir
bcl-2 gene
breast cancer
targeted therapy
url https://www.aimspress.com/article/doi/10.3934/molsci.2025003
work_keys_str_mv AT kannanmayuri micrornamediatedregulationofbcl2inbreastcancer
AT sundaramvickram micrornamediatedregulationofbcl2inbreastcancer
AT thirunavukarasouanand micrornamediatedregulationofbcl2inbreastcancer
AT kondamanisaravanan micrornamediatedregulationofbcl2inbreastcancer